Abstract Depression has emerged as a major cause of mortality globally
Preclinical models show that GLP-1 RAs reduce amyloid- plaque deposition, dampen neuroinflammation, and enhance synaptic plasticity
DS-8500a, an orally available G protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats
they have recently pivoted away from most compounded GLP-1s to partner directly for brand-names like Zepbound and Wegovy, which are often prohibitively expensive without insurance coverage
For example, the SURMOUNT-5 trial showed that tirzepatide (Zepbound) helped patients achieve roughly 20% weight loss, compared to 14% with semaglutide (Wegovy)
These are taken daily and designed to deliver similar appetite-regulating effects as the injectable versions